GENE ONLINE|News &
Opinion
Blog

2024-03-07| In-DepthSpecial

Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)

by Oscar Wu
Share To

Following the First Part of the article, let’s talk about the mechanism behind these magical pills.

Mechanisms of Action

(Source: please see References; Table: GeneOnline)

Semaglutide and Liraglutide

Paschos et al. found that semaglutide and liraglutide, both GLP-1 receptor agonists, mimic GLP-1 to suppress appetite and increase satiety in . This mechanism of action involves the activation of GLP-1 receptors, leading to reduced appetite and increased feelings of fullness.

Orlistat

Bloemendaal et al. reported that orlistat, a lipase inhibitor, blocks fat absorption in the intestines. By inhibiting the activity of lipase enzymes, orlistat reduces the hydrolysis of dietary fats, leading to decreased fat absorption and subsequent weight loss.

Tirzepatide

Tirzepatide, a dual-acting drug, was found to mimic GLP-1 and GIP to control appetite and satiety, while also increasing brown fat activity. This dual mechanism of action targets multiple pathways involved in weight regulation, potentially making it a more effective anti-obesity treatment.

Phentermine

Phentermine, an appetite suppressant, was shown to stimulate the central nervous system, thereby reducing appetite. This finding suggests that the mechanism of action of phentermine primarily involves neurological pathways that regulate appetite and food intake.

Naltrexone-Bupropion

Naltrexone-bupropion, which combines appetite suppression and craving reduction, targets both the physiological and psychological components of overeating and obesity. This dual approach may address the multifaceted nature of obesity and overeating behaviors.

Knowledge Gaps and Future Directions

Despite the progress in understanding the mechanisms of action of these anti-obesity drugs, there are still knowledge gaps that warrant further investigation. For instance, Pepino et al. conducted a study on the fatty acid translocase gene CD36 and lingual lipase and their influence on oral sensitivity to fat in obese subjects. However, the implications of these findings for the development of anti-obesity drugs remain unclear, highlighting the need for more research in this area.

Furthermore, additional studies are needed to elucidate the long-term efficacy and safety of these drugs, as well as their potential for combination therapies. Comparative effectiveness research could also provide valuable insights into the relative benefits and drawbacks of different anti-obesity drugs, helping to guide clinical decision-making.

In conclusion, the literature on the mechanisms of action of anti-obesity drugs demonstrates the diverse approaches taken to address the complex problem of obesity. Future research should aim to fill existing knowledge gaps, explore novel targets, and evaluate the long-term effectiveness and safety of these drugs, ultimately contributing to the development of more effective and personalized anti-obesity treatments.

References:

  1. van Bloemendaal, L. et al. GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans. Diabetes 63, 4186–4196 (2014).
  2. Paschos, G. K. et al. Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med 18, 1768–1777 (2012).
  3. Pepino, M. Y., Love-Gregory, L., Klein, S. & Abumrad, N. A. The fatty acid translocase gene CD36 and lingual lipase influence oral sensitivity to fat in obese subjects. Journal of Lipid Research 53, 561–566 (2012).
©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Author
Related Post
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
LATEST
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top